(MSOS) AdvisorShares Pure US - Overview
Etf: Cannabis, Hemp, Pharmaceuticals, Biotechnology, Life Sciences
| Risk 5d forecast | |
|---|---|
| Volatility | 85.8% |
| Relative Tail Risk | -12.2% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.57 |
| Alpha | -1.51 |
| Character TTM | |
|---|---|
| Beta | 0.774 |
| Beta Downside | 1.258 |
| Drawdowns 3y | |
|---|---|
| Max DD | 81.71% |
| CAGR/Max DD | -0.18 |
Description: MSOS AdvisorShares Pure US December 30, 2025
The AdvisorShares Pure US Cannabis ETF (MSOS) is an actively managed, non-diversified fund that allocates at least 80% of its net assets (including any investment-purpose borrowings) to U.S. companies whose core revenue-minimum 50%-comes from marijuana or hemp operations. Additionally, the portfolio must hold a minimum of 25% in the pharmaceuticals, biotechnology & life sciences sub-industry of health care.
Key market drivers include the ongoing federal-state regulatory patchwork, which historically creates binary price shocks when new states legalize adult-use cannabis; the U.S. cannabis market is projected by Grand View Research to reach roughly $30 billion in 2025, growing at a compound annual growth rate (CAGR) of ~12% from 2023-2025. MSOS’s expense ratio stands at 0.70%, and its top holdings (as of the latest filing) are concentrated in firms such as Curaleaf Holdings, Green Thumb Industries, and Trulieve, together accounting for over 40% of assets-a concentration risk that aligns with the fund’s “non-diversified” designation.
Overview
Ticker Symbol: MSOS
Type: ETF
Country of Origin: USA
ETF Category: Miscellaneous Sector
For a deeper quantitative breakdown, you might explore the fund’s metrics on ValueRay.
What is the price of MSOS shares?
Over the past week, the price has changed by +3.23%, over one month by -6.52%, over three months by +6.39% and over the past year by +12.43%.
Is MSOS a buy, sell or hold?
What are the forecasts/targets for the MSOS price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | - | - |
| Analysts Target Price | - | - |
| ValueRay Target Price | 4 | -3.6% |
MSOS Fundamental Data Overview February 07, 2026
EBIT TTM = 0.0 USD
EBITDA TTM = 0.0 USD
Long Term Debt = unknown (none)
Short Term Debt = unknown (none)
Debt = unknown
Net Debt = unknown
Enterprise Value = 821.9m USD (821.9m + (null Debt) - (null CCE))
Interest Coverage Ratio = unknown (Ebit TTM 0.0 / Interest Expense TTM 0.0)
EV/FCF = unknown (FCF TTM 0.0)
FCF Yield = 0.0% (FCF TTM 0.0 / Enterprise Value 821.9m)
FCF Margin = unknown (Revenue TTM is 0 or missing)
Net Margin = unknown
Gross Margin = unknown ((Revenue TTM 0.0 - Cost of Revenue TTM 0.0) / Revenue TTM)
Tobins Q-Ratio = unknown (Enterprise Value 821.9m / Total Assets none)
Interest Expense / Debt = unknown (Interest Expense 0.0 / Debt none)
Taxrate = 21.0% (US default 21%)
NOPAT = 0.0 (EBIT 0.0 * (1 - 21.00%))
Current Ratio = unknown (Total Current Assets none / Total Current Liabilities none)
Debt / Equity = unknown (Debt none)
Debt / EBITDA = unknown (Net Debt none / EBITDA 0.0)
Debt / FCF = unknown (Net Debt none / FCF TTM 0.0)
Total Stockholder Equity = 0.0 (from calculated bookValueOfEquity)
RoA = unknown (Net Income 0.0 / Total Assets none)
RoE = unknown (Net Income TTM 0.0 / Total Stockholder Equity 0.0)
RoCE = unknown (EBIT 0.0 / Capital Employed )
RoIC = unknown (NOPAT 0.0, Invested Capital 0.0, EBIT 0.0)
WACC = 8.77% (E(821.9m)/V(821.9m) * Re(8.77%) + (debt-free company))
Discount Rate = 8.77% (= CAPM, Blume Beta Adj.)
Fair Price DCF = unknown (Cash Flow 0.0)